Trk receptor Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S6760	LM22B-10	LM22B-10 is a small molecule TrkB/TrkC neurotrophin receptor co-activator. This compound selectively activates TrkB, TrkC, AKT and ERK in vivo and in vitro.	Theranostics, 2024, 14(4):1561-1582 Int J Mol Sci, 2024, 25(4)2408 Sci Rep, 2024, 14(1):12090
S6412	Altiratinib	Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor of TRK, Met (c-Met), TIE2, and VEGFR2 kinases with IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. This compound inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM.	J Microbiol, 2025, 63(2):e2409001 Theranostics, 2021, 11(20):9918-9936 Cold Spring Harb Mol Case Stud, 2021, 7(5)a006109
S2985	N-Acetyl-5-hydroxytryptamine	N-Acetyl-5-hydroxytryptamine (NAS, N-Acetylserotonin, Normelatonin, O-Demethylmelatonin), a precursor of melatonin, is a potent and selective agonist of TrkB receptor.	iScience, 2023, 26(3):106241
S0827	LM22A-4	LM22A-4 (LM 22A4) is a specific agonist of tyrosine kinase receptor B (TrkB) that reduces the development of tissue injury associated with spinal cord trauma.
S8788	CH7057288	CH7057288 is a potent and selective TRK inhibitor with IC50 values of 1.1 nM, 7.8 nM and 5.1 nM for TRKA, TRKB, and TRKC respectively.
E2390	Thalidomide-5-NH2-CH2-COOH	Thalidomide-5-NH2-CH2-COOH is a potent and selective inhibitor of tropomyosin receptor kinase (Trk).
S8407	PF-06273340	PF-06273340 is a highly potent, kinases elective, well-tolerated pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, Trk C, respectively.
S1124	BMS-754807	BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.	Cell Rep, 2025, 44(8):116149 Commun Med (Lond), 2025, 5(1):206 Front Cell Neurosci, 2024, 18:1441827
S1107	Danusertib (PHA-739358)	Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. It induces apoptosis, cell cycle arrest, and autophagy. This compound is in Phase 2.	Elife, 2024, 12RP92324 Sci Rep, 2024, 14(1):4303 Environ Mol Mutagen, 2024, 10.1002/em.22604
S8583	Repotrectinib (TPX-0005)	Repotrectinib (TPX-0005) is a novel ALK/ROS1/TRK inhibitor with the IC50 values of 1.01 nM for WT ALK, 1.26 nM for ALK(G1202R), and 1.08 nM for ALK(L1196M); it is also a potent SRC inhibitor (IC50 5.3 nM).	Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-25-0025 Commun Biol, 2024, 7(1):412 Cancer Discov, 2023, 13(3):598-615
S8573	Sitravatinib (MGCD516)	Sitravatinib (MGCD516, MG-516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.	Commun Biol, 2025, 8(1):1185 Res Sq, 2025, rs.3.rs-6431257 JCI Insight, 2022, e148717
S8901	Taletrectinib (DS-6051b)	Taletretinib (DS-6051b, AB-106) is a new-generation selective ROS1/NTRK inhibitor, with ic50 values of 0.207 nM, 0.622 nM, 2.28 nM, and 0.980 nM for ROS1, NTRK1, NTRK2, and NTRK3, respectively.	Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-25-0025 Sci Rep, 2024, 14(1):22191 Transl Lung Cancer Res, 2022, 11(11:2216-2229)
S8348	BMS-935177	BMS-935177 is a potent, reversible Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 value of 2.8 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which this compound is between 5- and 67-fold selective.	iScience, 2021, 24(9):102931 Am J Physiol Cell Physiol, 2021, 320(5):C902-C915 ScholarsArchive@OSU, 2020, 51
S8511	Belizatinib (TSR-011)	"Belizatinib (TSR-011) is a potent inhibitor of ALK (IC50=0.7 nM) and tropomyosin receptor kinase (TRK) (IC50 values less than 3 nM for TRK A, B, and C). "